FRNM

Freenome, Inc.

Freenome, Inc. (FRNM) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Profitability (C).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
C+
Factor Score 2.8 / 5.0
Growth
B
Factor Score 3.3 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
B
Factor Score 3.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -4.8
EV / EBITDA -13.3
Rev Growth YoY 106.5%
Gross Margin 0.0%
Price Return 3M -0.4%
Price Return 12M 8.0%
Catalyst Signal 0.00
Market Cap $1.2B
TTM Revenue $35.4M
Price / Sales 35.1
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.8) B (3.3) C (2.2) B (3.3) C+ (2.6) C+ (2.8)
2026-11-05 C+ (2.8) B (3.3) C (2.2) A- (4.0) C+ (2.7) B- (3.0)
2026-10-29 C+ (2.8) B (3.3) C (2.4) A- (4.1) C+ (2.7) B- (3.0)
2026-10-22 C+ (2.8) B (3.3) C (2.3) B+ (3.8) C+ (2.6) B- (3.0)
2026-10-15 C+ (2.8) B (3.3) C (2.3) B (3.4) C+ (2.6) B- (2.9)
Page 1 of 3